Myriad Genetics Reports Fiscal Second-Quarter 2015 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- Nasdaq leads Wall Street gains as SpaceX, Super Micro boost AI sentiment
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- SpaceX, Tesla shares rise after Musk says committees exploring possible merger
- Brent falls as Iran's president discusses mediation with Pakistani army chief
- Abbott plans to spin off its nutrition unit as a standalone public company
- Alphabet shares drop ahead of earnings next week
- Nasdaq leads Wall Street gains as SpaceX, Super Micro boost AI sentiment
- Crude Inventory Fell 3.06 Million Barrels Last Week - EIA
- US orders diplomats to depart Saudi Arabia amid Houthi strikes
Myriad Genetics (MYGN) Tops Q2 EPS by 5c; Cuts FY15 Outlook
February 3, 2015 4:08 PM ESTMyriad Genetics (NASDAQ: MYGN) reported Q2 EPS of $0.40, $0.05 better than the analyst estimate of $0.35. Revenue for the quarter came in at $184.4 million versus the consensus estimate of $183.41 million.
Myriad Genetics sees FY2015 EPS of $1.50 - $1.55, versus the consensus of $1.85. Myriad Genetics sees FY2015... More



